Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Pancreatic cancer is characterised by invasive tumour spread and early metastasis formation. During epithelial-mesenchymal transition, loss of the cell adhesion molecule E-cadherin is frequent and can be caused by genetic or epigenetic modifications, recruitment of transcriptional activators/repressors or post-translational modifications. A study was undertaken to investigate how E-cadherin expression in human pancreatic adenocarcinoma and pancreatic cancer cell lines is regulated. METHODS: In 25 human pancreatic cancer resection specimens, the coding region of the E-cadherin gene (CDH1) was sequenced for somatic mutations. The tumour samples and 11 established human pancreatic cancer cell lines were analysed by immunohistochemistry, western blot analysis, chromatin immunoprecipitation and methylation-specific PCR. The role of specific histone deacetylase inhibitors (HDACi) on pancreatic tumour cell migration and proliferation was studied in vitro. RESULTS: Neither somatic mutations nor CDH1 promoter hypermethylation were found to be responsible for downregulation of E-cadherin in pancreatic cancer. In the transcriptionally active CDH1 promoter, acetylation of histones H3 and H4 was detected whereas HDAC1 and HDAC2 were found attached only to a silent promoter. Expression of ZEB1, a transcription factor known to recruit HDACs, was seen in E-cadherin-deficient cell lines in which ZEB1/HDAC complexes were found attached to the CDH1 promoter. Moreover, knockdown of ZEB1 prevented HDAC from binding to the CDH1 promoter, resulting in histone acetylation and expression of E-cadherin. HDACi treatment attenuated tumour cell migration and proliferation. CONCLUSIONS: These findings imply an important role for histone deacetylation in the downregulation of E-cadherin in human pancreatic cancer. Recruitment of HDACs to the CDH1 promoter is regulated by the transcription factor ZEB1, and inhibition of HDACs may be a promising antitumour therapy for pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81656-6 · Cited by 6,143
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,855
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Batlle, E., Sancho, E., Francí, C., Domínguez, D., Monfar, M., Baulida, J., & García de Herreros, A. (2000) · Nature Cell Biology · doi:10.1038/35000034 · Cited by 2,666
Molecular requirements for epithelial–mesenchymal transition during tumor progression
Huber, M. A., Kraut, N., & Beug, H. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.08.001 · Cited by 1,821
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584 · cited 1×
“However, the antitumour activity of HDACi may reflect effects on different genes that are associated with proliferation, apoptosis and the cell cycle.(41) 42 HDACs also act on non-histone proteins, and we observed increased caspase-3 levels in PaTu-8988Tcells after HDACi treatment which can affect cell proliferation b…”
BackgroundHistone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542 · cited 1×
“Other epigenetic changes involve the reversible acetylation of histones by antagonistic acetyltransferases (HATs) and members of the deacetylase family (HDACs).(22) Nucleosomes consist of four core histones (H2A, H2B, H3 and H4) which can all be modified by acetylation.”
BackgroundLoss of E-Cadherin Promotes Metastasis via Multiple Downstream Transcriptional Pathways
Onder, T. T., Gupta, P. B., Mani, S. A., Yang, J., Lander, E. S., & Weinberg, R. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2938 · Cited by 1,522
The Two-Handed E Box Binding Zinc Finger Protein SIP1 Downregulates E-Cadherin and Induces Invasion
Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L., Bruyneel, E., Mareel, M., Huylebroeck, D., & van Roy, F. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00260-x · Cited by 1,394
Bolós, V., Peinado, H., Pérez-Moreno, M. A., Fraga, M. F., Esteller, M., & Cano, A. (2003) · Journal of Cell Science · doi:10.1242/jcs.00224 · Cited by 1,100
Yang, X.-J., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210599 · Cited by 940
Peinado, H., Ballestar, E., Esteller, M., & Cano, A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.306-319.2004 · Cited by 763
Mutations of the human E-cadherin (CDH1) gene
Berx, G., Becker, K.-F., Höfler, H., & van Roy, F. (1998) · Human Mutation · doi:10.1002/(sici)1098-1004(1998)12:4<226::aid-humu2>3.0.co;2-d · Cited by 607
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
Cao, Q., Yu, J., Dhanasekaran, S. M., Kim, J. H., Mani, R.-S., Tomlins, S. A., Mehra, R., Laxman, B., Cao, X., Yu, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.333 · Cited by 583
Weichert, W., Röske, A., Gekeler, V, Beckers, T., Stephan, C., Jung, K., Fritzsche, F. R., Niesporek, S., Denkert, C., Dietel, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604199 · Cited by 477
Pérez-Moreno, M. A., Locascio, A., Rodrigo, I., Dhondt, G., Portillo, F., Nieto, M. A., & Cano, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100827200 · Cited by 440
Polycomb Complex 2 Is Required for E-cadherin Repression by the Snail1 Transcription Factor
Herranz, N., Pasini, D., Díaz, V. M., Francí, C., Gutierrez, A., Dave, N., Escrivà, M., Hernandez-Muñoz, I., Di Croce, L., Helin, K., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00323-08 · Cited by 437
Hotz, B., Arndt, M., Dullat, S., Bhargava, S., Buhr, H.-J., & Hotz, H. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2926 · Cited by 418
HDAC expression and clinical prognosis in human malignancies
Weichert, W. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.10.047 · Cited by 409
Brooks-Wilson, A. R., Kaurah, P., Suriano, G., Leach, S., Senz, J., Grehan, N., Butterfield, Y. S. N., Jeyes, J., Schinas, J., Bacani, J., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.018275 · Cited by 361
von Burstin, J., Eser, S., Paul, M. C., Seidler, B., Brandl, M., Messer, M., von Werder, A., Schmidt, A., Mages, J., Pagel, P., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.004 · Cited by 356
Keller, G., Vogelsang, H., Becker, I., Hutter, J., Ott, K., Candidus, S., Grundei, T., Becker, K.-F., Mueller, J., Siewert, J. R., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65129-2 · Cited by 287
Molecular components of the adherens junction
Niessen, C. M., & Gottardi, C. J. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.12.015 · Cited by 282
Mutations of the E–cadherin gene in human gynecologic cancers
Risinger, J. I., Berchuck, A., Kohler, M. F., & Boyd, J. (1994) · Nature Genetics · doi:10.1038/ng0594-98 · Cited by 280
Weiss, F. U., Marques, I. J., Woltering, J. M., Vlecken, D. H., Aghdassi, A., Partecke, L. I., Heidecke, C., Lerch, M. M., & Bagowski, C. P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.065 · Cited by 257
Self-citationKumagai, T., Wakimoto, N., Yin, D., Gery, S., Kawamata, N., Takai, N., Komatsu, N., Chumakov, A., Imai, Y., & Koeffler, H. P. (2007) · International Journal of Cancer · doi:10.1002/ijc.22558 · Cited by 182
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA
Fritsche, P., Seidler, B., Schüler, S., Schnieke, A., Göttlicher, M., Schmid, R. M., Saur, D., & Schneider, G. (2009) · Gut · doi:10.1136/gut.2009.180711 · Cited by 167
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
Fritzsche, F. R., Weichert, W., Röske, A., Gekeler, V., Beckers, T., Stephan, C., Jung, K., Scholman, K., Denkert, C., Dietel, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-381 · Cited by 163
Miyake, K., Yoshizumi, T., Imura, S., Sugimoto, K., Batmunkh, E., Kanemura, H., Morine, Y., & Shimada, M. (2008) · Pancreas · doi:10.1097/mpa.0b013e31815f2c2a · Cited by 155
Regulation of gene expression by transcription factor acetylation
Bannister, A. J., & Miska, E. A. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000758 · Cited by 151
Ouaïssi, M., Sielezneff, I., Silvestre, R., Sastre, B., Bernard, J., Simony-Lafontaine, J., Payan, M. J., Dahan, L., Pirró, N., Seitz, J. F., et al. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9940-z · Cited by 131
Mayerle, J. V., Schnekenburger, J., Krüger, B., Kellermann, J., Ruthenbürger, M., Weiß, F. U., Nalli, A., Domschke, W., & Lerch, M. M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.002 · Cited by 130
Self-citationElsässer, H. P., Lehr, U., Agricola, B., & Kern, H. F. (1992) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02890431 · Cited by 112
Bush, K. T., Tsukamoto, T., & Nigám, S. K. (2000) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2000.278.5.f847 · Cited by 108
The role of epigenetic alterations in pancreatic cancer
Sato, N., & Goggins, M. (2006) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s00534-005-1057-1 · Cited by 102
Lehmann, A., Denkert, C., Budczies, J., Buckendahl, A., Darb‐Esfahani, S., Noske, A., Müller, B. M., Bahra, M., Neuhaus, P., Dietel, M., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-395 · Cited by 91
Mayerle, J. V., Frieß, H., Büchler, M. W., Schnekenburger, J., Weiß, F. U., Zimmer, K.-P., Domschke, W., & Lerch, M. M. (2003) · Gastroenterology · doi:10.1053/gast.2003.50142 · Cited by 68
Self-citationPancreatitis and Calcium Signalling: Report of an International Workshop
Sutton, R., Petersen, O. H., & Pandol, S. J. (2008) · Pancreas · doi:10.1097/mpa.0b013e3181675010 · Cited by 59
Evaluation of Pancreatic Cancer With Raman Spectroscopy in a Mouse Model
Pandya, A. K., Serhatkulu, G. K., Cao, A., Kast, R. E., Dai, H., Rabah, R., Poulik, J., Banerjee, S., Naik, R., Adsay, V., et al. (2008) · Pancreas · doi:10.1097/mpa.0b013e31815a3f1c · Cited by 41
Liu, Y., Yi, H., Zhao, Y., Ismail, T., Wong, Y., & Eu, K. W. (2008) · Cancer Investigation · doi:10.1080/07357900701837168 · Cited by 23
Cited by
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Serrano-Gomez, S. J., Maziveyi, M., & Alahari, S. K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0502-x · Cited by 814
A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition
Xu, W., Yang, Z., & Lu, N. (2015) · Cell Adhesion & Migration · doi:10.1080/19336918.2015.1016686 · Cited by 608
Context-dependent EMT programs in cancer metastasis
Aiello, N. M., & Kang, Y. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181827 · Cited by 584
Metadata
- Authors
- Aghdassi, A., Sendler, M., Guenther, A., Mayerle, J., Behn, C.-O., Heidecke, C.-D., Friess, H., Büchler, M., Evert, M., Lerch, M. M., & Weiss, F. U.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2011-12-05
- Volume
- 61
- Issue
- 3
- Pages
- 439-448
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2141542227
- Cited by
- 289
- References
- 47
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.